• Bazedoxifene and IL-6/GP130 Signaling in Cancer

  2026-08-19

  The 2024 review by Shi and colleagues examines Bazedoxifene, a selective estrogen receptor modulator, as a repurposing candidate that may inhibit oncogenic IL-6/GP130 signaling. Its key contribution is to connect structure-guided drug repositioning with evidence from cancer models, while identifying the mechanistic and translational questions that must be resolved before oncology trials.

• Methylprednisolone in Bone Remodeling Assays

  2026-08-18

  Methylprednisolone is more than a glucocorticoid exposure reagent: it can serve as a controlled perturbation for connecting inflammatory signaling, osteoclast activity, and tissue-level bone injury. This article translates a rat osteonecrosis study into practical assay-design decisions while addressing model interpretation, formulation, and translational limits.

• Angiotensin II: From Pressure Signal to Heart Failure

  2026-08-18

  Angiotensin II is more than a vasopressor challenge: it is a versatile translational perturbation linking GPCR signaling, vascular remodeling, cardiomyocyte stress, and macrophage interferon biology. This article translates recent Mertk–IFN-β findings into practical model-selection, validation, and workflow strategies.

• PUFA-PL Enzymes in Rice Blast Pathogenicity

  2026-08-17

  The 2024 Mycology study links Magnaporthe oryzae pathogenicity to Fad2- and Acsl4-dependent production of polyunsaturated fatty acid phospholipids and ferroptosis-associated lipid peroxidation. Genetic analysis, targeted lipidomics, iron-mediated rescue, and interaction studies together identify PUFA-PL metabolism as a potential disease-control target, while also defining important limits on causal interpretation.

• CHIR 99021 Trihydrochloride in Organoids

  2026-08-16

  CHIR 99021 trihydrochloride is a selective GSK-3 inhibitor for probing the balance between organoid self-renewal, proliferation, and lineage diversification. This article connects its molecular action to practical assay design, metabolic disease modeling, and the key insights of a tunable human intestinal organoid study.

• Superoxide Dismutase (SOD) Activity Assay Kit

  2026-08-15

  The Superoxide Dismutase (SOD) Activity Assay Kit K2035 provides a rapid colorimetric method for measuring SOD activity in biological fluids through XO-driven WST-1 reduction at 450 nm. It is suited to research workflows such as oxidative stress assay, antioxidative enzyme assay, and cancer research, but it does not directly measure hydrogen peroxide, total reactive oxygen species, or clinical status.

• Coumestrol: Designing Mechanism-Resolved Assays

  2026-08-15

  Coumestrol is a phytoestrogen estrogen receptor antagonist with a distinctive concentration-dependent nuclear receptor and ferroptosis research profile. This guide shows how to separate estrogen receptor signaling pathway effects from PMAIP1-linked ferroptosis in rheumatoid arthritis synoviocyte assays.

• SEMA3E, β-Catenin, and Beige Fat Thermogenesis

  2026-08-14

  A 2026 mouse study identifies the secreted semaphorin SEMA3E as a regulator of beige adipocyte differentiation and non-shivering thermogenesis in inguinal white adipose tissue. Through gain- and loss-of-function experiments, mitochondrial respiration analyses, RNA sequencing, and pathway rescue, the work connects SEMA3E to β-catenin signaling and thermogenic remodeling.

• L-Phenylephrine in Adrenergic α1A Assays

  2026-08-14

  Build more interpretable α1A receptor experiments with L-Phenylephrine across vascular, cardiac, neural, and baroreflex models. This guide translates sex-aware hypertension findings into practical dose-response design, controls, workflow parameters, and troubleshooting strategies.

• MMP-2-Responsive Liposomes for Sequential Immunotherapy

  2026-08-13

  The reference study developed NLG919@Lip-pep1, an MMP-2-responsive liposome designed to deliver the PD-1 pathway blockade peptide AUNP-12 before exposing a secondary tumor-targeting module carrying the IDO inhibitor NLG919. In breast cancer models, this cascade-oriented design was reported to improve immune activation and remodel immunosuppressive tumor biology more effectively than uncoordinated single-agent treatment.

• NSC 87877 Shp2 Inhibitor Workflow Guide

  2026-08-13

  Use NSC 87877 to separate SHP2-dependent signaling from upstream receptor events in microglial, cancer, and inflammatory pain models. This workflow translates the Nespas/miR-383-3p/SHP2 findings after ischemic stroke into practical pharmacology, controls, and troubleshooting decisions.

• AL-8810: Prostaglandin F2α Antagonist

  2026-08-12

  AL-8810 is a prostaglandin F2α antagonist that selectively targets the FP receptor for mechanistic cell and tissue research. Product benchmarks and a peer-reviewed mouse menstrual-like model support its use in studying FP receptor signaling, vascular dynamics, smooth muscle responses, and endometrial breakdown.

• AEBSF.HCl in Protease and Necroptosis Workflows

  2026-08-12

  AEBSF.HCl gives researchers irreversible control over serine protease activity in cell lysis, APP-processing, amyloid, and immune cytotoxicity workflows. Its strongest value in necroptosis research is as a pathway-dissection tool—not as a substitute for direct cathepsin B inhibition.

• Troxerutin, TRPM7, and Diabetic Cognitive Dysfunction

  2026-08-11

  A 2025 World Journal of Diabetes study identifies the TRPM7/calcineurin/Drp1^Ser637 axis as a mediator of abnormal mitochondrial fission and neuronal injury in diabetic cognitive dysfunction. Using diabetic mice and high-glucose hippocampal neurons, the authors show that troxerutin improves behavioral and mitochondrial outcomes by suppressing this pathway, while also highlighting important limits for translation beyond the tested models.

• 1-methyl Adenosine: From Signal to Strategy

  2026-08-10

  1-methyl Adenosine, also called 1-methyl Ado, is becoming a strategically useful bridge between RNA turnover, cancer metabolism studies, and biomarker discovery. This thought-leadership guide explains how to distinguish mechanistic evidence from correlation, build a defensible UHPLC–MS/MS workflow, and use a fit-for-purpose reagent strategy for translational research.

459 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page